Analysts Offer Predictions for MREO Q1 Earnings

Key Points

• Leerink Partners predicts that Mereo BioPharma Group will report Q1 2026 earnings of ($0.01) per share, with full-year earnings expected at ($0.03) per share.
• Mereo BioPharma's stock was recently downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Needham & Company maintains a "buy" rating with a target price of $5.00.
• The company's stock trades at around $1.68, with a market cap of $266.33 million, reflecting a fluctuation from a 12-month low of $1.47 to a high of $5.02.

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 earnings estimates for Mereo BioPharma Group in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group's Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.04 EPS and FY2027 earnings at $0.03 EPS.

A number of other equities analysts also recently weighed in on MREO. Wall Street Zen downgraded shares of Mereo BioPharma Group from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Needham & Company LLC set a $5.00 target price on shares of Mereo BioPharma Group and gave the stock a "buy" rating in a report on Thursday, July 10th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $7.20.

Mereo BioPharma Group Stock Performance

MREO traded down $0.06 during trading on Thursday, reaching $1.68. 99,373 shares of the stock were exchanged, compared to its average volume of 1,763,836. The stock has a market cap of $266.33 million, a P/E ratio of -23.93 and a beta of 0.47. Mereo BioPharma Group has a twelve month low of $1.47 and a twelve month high of $5.02. The stock's 50 day moving average price is $2.23 and its two-hundred day moving average price is $2.39.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $7.80 million.

Hedge Funds Weigh In On Mereo BioPharma Group

Hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. increased its position in Mereo BioPharma Group by 187.9% during the fourth quarter. Ameriprise Financial Inc. now owns 94,456 shares of the company's stock worth $331,000 after acquiring an additional 61,642 shares during the period. GAMMA Investing LLC increased its position in Mereo BioPharma Group by 109.5% during the first quarter. GAMMA Investing LLC now owns 18,855 shares of the company's stock worth $42,000 after acquiring an additional 9,854 shares during the period. XTX Topco Ltd bought a new position in Mereo BioPharma Group during the fourth quarter worth about $133,000. Walleye Capital LLC bought a new position in Mereo BioPharma Group during the fourth quarter worth about $454,000. Finally, Tema Etfs LLC bought a new position in Mereo BioPharma Group during the fourth quarter worth about $3,117,000. 62.83% of the stock is owned by institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.